A tragic RSV vaccine trial in the 1960s set the field back for decades. Here’s how scientists finally made breakthroughs in ...

MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 ...

On Patient Safety Day this September, Hope From Within (HFW), a multi-stakeholder cancer advocacy campaign spearheaded by MSD ...

MSD in the Philippines recently donated 1,500 doses of the human papillomavirus (HPV) vaccine to the PHAPCares Foundation, ...

In this post-BIO virtual interview, editor-in-chief Jonah Comstock speaks with Iya Khalil, VP and head of data, AI, and ...

When Laura Ehrlich gave birth to her first child in 2020, the COVID-causing virus wasn’t the only threat facing her son. Born ...

Respiratory syncytial virus (RSV) continues to affect infants and older and immunocompromised people around the world. These ...

At first, Ethel Branch thought her two-year-old son, Patro, had a cold or maybe the flu. Frantic, Branch rushed Patro to the ...

With the numbers of people learning to drive manual cars steadily declining, what will that mean for industries that still ...

Penny stocks carry a good deal of risk. It’s why the US SEC says, “Penny stocks may trade infrequently — which means that it ...

Two pharma companies developing lipid-lowering drugs, MSD and Ionis, have reported positive phase 3 data that open the way for regulatory filings in the coming months. First up, MSD, which chalked up ...

When Air Chief Marshal A P Singh flies the final MiG-21 sortie with the call sign ‘Badal 3’, Chandigarh will end the chapter ...